Stockreport

Artiva Biotherapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Artiva Biotherapeutics, Inc.  (ARTV) 
PDF Over 100 patients treated with AlloNK across autoimmune and oncology indications Refractory rheumatoid arthritis (RA) prioritized as lead indication following FDA Fast [Read more]